Karl-johan J. Myren
Stockholm, AB 11368, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Use of Real-World Evidence in Health Technology Assessments of Non-Oncology Rare Disease Therapies.
Journal: Journal of market access & health policy
Published: February 10, 2026
The impact of relapse on patient disability, clinical outcomes, and subsequent burdens to patients with neuromyelitis optica spectrum disorder and caregivers.
Journal: Multiple sclerosis journal - experimental, translational and clinical
Published: October 03, 2025
Clinical Outcomes and Disease Management for Patients with Paroxysmal Nocturnal Haemoglobinuria in China: Results from a Real-World Study.
Journal: Drugs - real world outcomes
Published: July 29, 2025
Patient-reported outcomes and daily activity assessed with a digital wearable device in patients with paroxysmal nocturnal hemoglobinuria treated with ravulizumab: REVEAL, a prospective, observational study.
Journal: Health and quality of life outcomes
Published: February 27, 2024
Impact of Lactate Dehydrogenase and Hemoglobin Levels on Clinical Outcomes in Patients With Paroxysmal Nocturnal Hemoglobinuria: Results From the National Korean PNH Registry.
Journal: Journal of Korean medical science
Published: August 07, 2023
Japanese patient preferences between ravulizumab and eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: February 12, 2023
Indirect and Direct Mapping of the Cancer-Specific EORTC QLQ-C30 onto EQ-5D-5L Utility Scores.
Journal: Applied health economics and health policy
Published: August 25, 2021
Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the Netherlands.
Journal: The European journal of health economics : HEPAC : health economics in prevention and care
Published: August 19, 2021
Norm-based comparison of the quality-of-life impact of ravulizumab and eculizumab in paroxysmal nocturnal hemoglobinuria.
Journal: Orphanet journal of rare diseases
Published: June 14, 2021
No impact of Asian ethnicity on EORTC QLQ-C30 scores: Group differences and differential item functioning in paroxysmal nocturnal hemoglobinuria.
Journal: Health and quality of life outcomes
Published: June 07, 2021
A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome.
Journal: Journal of medical economics
Published: October 01, 2020
Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden.
Journal: Journal of medical economics
Published: November 16, 2017
Last Updated: 09/26/2026